Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
Kyverna Therapeutics announced three key leadership appointments to support its next growth phase in developing cell therapies for autoimmune diseases. Dan Maziasz joins as Chief Business Officer, bringing 25 years of experience from companies like Atara Biotherapeutics and Kite Pharma. Cara Bauer becomes Chief Human Resources Officer, with over 25 years of global HR leadership experience, notably at Kite and Netflix. Tracy Rossin joins as SVP of Corporate Affairs, Communications and Investor Relations, bringing 20 years of strategic communications experience from Kite and AstraZeneca.
As part of his appointment, Maziasz received an inducement grant of options to purchase 350,000 shares at $4.86 per share, vesting over four years with 25% vesting after one year and the remainder monthly.
Kyverna Therapeutics ha annunciato tre importanti nomine dirigenziali per supportare la propria prossima fase di crescita nello sviluppo di terapie cellulari per le malattie autoimmuni. Dan Maziasz si unisce come Chief Business Officer, portando con sé 25 anni di esperienza in aziende come Atara Biotherapeutics e Kite Pharma. Cara Bauer diventa Chief Human Resources Officer, con oltre 25 anni di esperienza nella leadership globale delle risorse umane, in particolare presso Kite e Netflix. Tracy Rossin entra come SVP degli Affari Aziendali, Comunicazione e Relazioni con gli Investitori, apportando 20 anni di esperienza in comunicazioni strategiche da Kite e AstraZeneca.
Come parte della sua nomina, Maziasz ha ricevuto un'offerta di opzioni per acquistare 350.000 azioni a $4,86 per azione, con maturazione su un periodo di quattro anni, con il 25% che matura dopo un anno e il resto mensilmente.
Kyverna Therapeutics anunció tres nombramientos clave en el liderazgo para apoyar su próxima fase de crecimiento en el desarrollo de terapias celulares para enfermedades autoinmunes. Dan Maziasz se une como Director de Negocios, aportando 25 años de experiencia de empresas como Atara Biotherapeutics y Kite Pharma. Cara Bauer se convierte en Directora de Recursos Humanos, con más de 25 años de experiencia en liderazgo global de recursos humanos, notablemente en Kite y Netflix. Tracy Rossin se une como SVP de Asuntos Corporativos, Comunicaciones y Relaciones con Inversores, trayendo consigo 20 años de experiencia en comunicaciones estratégicas de Kite y AstraZeneca.
Como parte de su nombramiento, Maziasz recibió una concesión inducida de opciones para comprar 350,000 acciones a $4.86 por acción, con un periodo de consolidación de cuatro años, siendo el 25% consolidable tras un año y el resto mensualmente.
Kyverna Therapeutics는 자가면역 질환을 위한 세포 치료제를 개발하는 다음 성장 단계를 지원하기 위해 세 가지 주요 리더십 임명을 발표했습니다. Dan Maziasz는 Chief Business Officer로 합류하며, Atara Biotherapeutics와 Kite Pharma와 같은 회사에서 25년의 경험을 가지고 있습니다. Cara Bauer는 Chief Human Resources Officer가 되어, 특히 Kite와 Netflix에서 25년 이상의 글로벌 HR 리더십 경험을 보유하고 있습니다. Tracy Rossin은 SVP로서 기업 관계, 커뮤니케이션 및 투자자 관계 부서에 합류하며, Kite와 AstraZeneca에서 20년의 전략적 커뮤니케이션 경험을 가지고 있습니다.
그의 임명의 일환으로, Maziasz는 주당 $4.86에 350,000주를 구매할 수 있는 옵션 부여를 받았으며, 4년 동안 25%가 1년 후에 만기되고 나머지는 매달 만기됩니다.
Kyverna Therapeutics a annoncé trois nominations clés au sein de son équipe de direction pour soutenir sa prochaine phase de croissance dans le développement de thérapies cellulaires pour les maladies auto-immunes. Dan Maziasz rejoint en tant que Directeur Commercial, apportant 25 ans d'expérience dans des entreprises telles qu'Atara Biotherapeutics et Kite Pharma. Cara Bauer devient Directrice des Ressources Humaines, avec plus de 25 ans d'expérience en leadership RH mondial, notamment chez Kite et Netflix. Tracy Rossin rejoint l'équipe en tant que SVP des Affaires Corporatives, de la Communication et des Relations avec les Investisseurs, apportant 20 ans d'expérience en communications stratégiques provenant de Kite et d'AstraZeneca.
Dans le cadre de sa nomination, Maziasz a reçu une attribution d'options pour acheter 350 000 actions à 4,86 $ par action, avec une acquisition échelonnée sur quatre ans, avec 25 % après un an et le reste mensuellement.
Kyverna Therapeutics hat drei wichtige Führungspositionen bekannt gegeben, um die nächste Wachstumsphase in der Entwicklung von Zelltherapien für Autoimmunerkrankungen zu unterstützen. Dan Maziasz tritt als Chief Business Officer bei, mit 25 Jahren Erfahrung in Unternehmen wie Atara Biotherapeutics und Kite Pharma. Cara Bauer wird Chief Human Resources Officer und bringt über 25 Jahre globale Führungserfahrung im Personalwesen mit, insbesondere bei Kite und Netflix. Tracy Rossin kommt als SVP für Unternehmensangelegenheiten, Kommunikation und Investor Relations hinzu und bringt 20 Jahre strategische Kommunikationserfahrung aus Kite und AstraZeneca mit.
Im Rahmen seiner Ernennung erhielt Maziasz ein Angebot zum Erwerb von Optionen für 350.000 Aktien zu je 4,86 USD pro Aktie, die über vier Jahre vesten, wobei 25 % nach einem Jahr und der Rest monatlich vesten.
- Strategic expansion of executive team with experienced leaders from major biotech companies
- Acquisition of expertise in cell therapy from key industry players (Atara, Kite)
- Addition of global business development and strategic planning capabilities
- Significant equity compensation package indicating high executive costs
Key Leadership Appointments Bring New Skills and Capabilities to Organization
"I'm pleased to welcome three industry leaders to our Kyverna team," said Warner Biddle, Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases."
Mr. Maziasz brings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies. Mr. Maziasz most recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Mr. Maziasz led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Mr. Maziasz was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US,
Ms. Bauer brings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, a Gilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build an Entertainment Studio separate from the core gaming business. Ms. Bauer has also held various HR leadership roles at companies such as Netflix, Amgen, Gartner and Novo Nordisk.
Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications. Ms. Rossin also spent more than 12 years at AstraZeneca/MedImmune, where she held multiple
Inducement Grant
In connection with the appointment of Mr. Maziasz as Kyverna's Chief Business Officer, on December 9, 2024, Kyverna granted Mr. Maziasz an option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024, and was granted as an inducement material to Mr. Maziasz's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in
For more information, please visit https://kyvernatx.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-strengthens-leadership-team-to-accelerate-next-phase-of-growth-302331659.html
SOURCE Kyverna Therapeutics
FAQ
Who are the new executives joining Kyverna Therapeutics in December 2024?
What is the value and terms of Dan Maziasz's stock option grant at Kyverna?
What experience does Dan Maziasz bring to Kyverna Therapeutics?
What is Cara Bauer's background before joining Kyverna Therapeutics?
